A list of companies appearing on U.S. metronidazole packages is not the same as a list of factories manufacturing an FDA-approved drug. FDA’s National Drug Code (NDC) Directory is populated using labeler-submitted listing information. A labeler may be the actual manufacturer, a repackager, a relabeler or a private-label company. The name printed on a pharmacy bottle therefore does not always identify the plant that physically manufactured the medicine. The correct commercial question is which exact finished drug product is listed, whether its approval status is verified and what route and strength appear on its official labeling.
Examples show why the distinctions matter. DailyMed identifies Cambridge Therapeutics Technologies, LLC on an archived repackaged oral-tablet label, Encube Ethicals, Inc. on a 0.75% topical-gel label, and Alembic Pharmaceuticals Inc. on a 375 mg oral-capsule label. These are identifiable product-specific labeler or packager records, not a ranking of drug makers or an assertion of current stock. An establishment entry can provide further information about manufacturing operations, and the FDA approval record should be checked separately.
This index explains a reproducible verification workflow rather than ranking unverified manufacturers or claiming a current pharmacy supplier list. Compare the oral generic guide with the vaginal generic guide and the broader substitution rules. Each represents a different aspect of product identity. Approval data, packaging data and retailer inventory should be checked independently when a particular drug is being dispensed.
The table separates four kinds of evidence used to identify U.S. metronidazole suppliers: NDC listing, DailyMed labeling, FDA approval and therapeutic-equivalence records, and the physical product a pharmacy dispenses. These sources answer different questions. For example, an NDC labeler can be a repackager, while a DailyMed establishment entry may separately identify manufacturing and packaging operations. Neither record alone proves what any pharmacy has available now.
Start with the exact product: oral tablet or capsule, vaginal gel, or skin gel, cream or lotion. Next identify its strength and route, then compare the labeler, application number and any available therapeutic-equivalence determination. The examples below are documented regulatory records, not rankings of companies, promises of present-day stock or evidence that oral and topical drugs can be substituted.
| Record to check | What it establishes | What it does NOT establish |
|---|---|---|
| NDC directory labeler name | Entity that submitted label listing | That entity physically made the drug |
| Product NDC | Listed drug product identity | FDA approval or active pharmacy stock |
| Package NDC | Listed package size/type | Guaranteed retail availability |
| DailyMed SPL | Label and reported manufacturer/packager fields | Regulatory approval of every listed product |
| Orange Book NDA/ANDA | FDA approved application and dosage form | Which pharmacy stocks the product |
| Orange Book TE code | Reference-product equivalence evaluation | Cross-route therapeutic interchangeability |
| Oral 250/500 mg tablet | Strength, imprint, labeler for that tablet | Equivalence to a capsule or gel |
| 375 mg capsule / ER 750 mg | Specific capsule or release system | Generic substitution with ordinary tablets |
| Vaginal versus dermal gel | Distinct route and approved uses | Interchangeability based on 0.75% |
| Actual physical manufacturer | Needs verified establishment/supplier record | Can always be inferred from brand name |
| Oral tablet labeler example | Cambridge Therapeutics Technologies, LLC, is identified on a repackaged 250 mg tablet listing | This does not identify Cambridge as the tablet manufacturer |
| Skin-gel record example | Encube Ethicals, Inc., labels an ANDA 0.75% topical gel listing | The separate establishment record is needed to identify manufacturing operations |
| Oral capsule labeler example | Alembic Pharmaceuticals Inc., is listed as packager of 375 mg oral capsules | A capsule application is not evidence of a tablet or vaginal-gel product |
FDA’s NDC directory provides information that labelers electronically submit about finished drug products and packages. These records help identify what company is responsible for listing an item, but FDA cautions that listing does not indicate independent verification or approval.
A search result containing an NDC should not be used as proof that a generic metronidazole drug is approved, currently sold or physically made by the named labeler. The focused guide to metronidazole tablets provides a narrower look at that issue and should not be read as a universal substitution recommendation.
The company appearing on a bottle may be a manufacturer, labeler, repackager or distributor. DailyMed provides a concrete case: the Cambridge Therapeutics Technologies, LLC metronidazole tablet label identifies the product as repackaged and records a source NDC. The company name on that repackaged label is not sufficient evidence that Cambridge physically manufactured the original tablets.
A different DailyMed record for Encube Ethicals 0.75% topical metronidazole gel identifies Encube Ethicals, Inc. as the labeler and includes an establishment listing for Encube Ethicals Private Limited with manufacturing and packaging operations. Cite the specific label, product and establishment when making those statements. Do not generalize one corporate relationship to every metronidazole dosage form or every package marketed by the same group.
The Orange Book identifies approved new drugs and generics, including route, dosage form, strength, applications and therapeutic equivalence where applicable. An ANDA is a regulatory application, not proof that every NDC under a similar trade name is a matched generic.
For a genuine approval check, find the application and reference product rather than treating the NDC number as a substitute for the FDA drug-approval record. The focused guide to metronidazole 500mg provides a narrower look at that issue and should not be read as a universal substitution recommendation.
A company recorded for metronidazole oral capsules is not necessarily recorded for an oral tablet or vaginal gel. For example, the Alembic Pharmaceuticals Inc. DailyMed record documents a metronidazole 375 mg oral capsule under ANDA 079065. The Encube 0.75% product record, by contrast, is a skin-use gel under ANDA 077547. Those records describe different pharmaceutical categories, not substitute retail items.
A useful index therefore has a row for route, dosage form, strength, application and labeler before company names are compared. For the regulatory distinction between vaginal and dermal gels, see vaginal versus topical metronidazole gel. A combined alphabetical list of companies without product identifiers would conceal exactly the information patients and pharmacists need.
DailyMed and listing data can retain historical brands and marketing histories. Flagyl 250/500 mg branded tablets and older product lines should not be treated as currently stocked merely because records are searchable.
Approval, listing, marketing date and shelf availability are four different concepts. Confirm the actual legal product status through current official records and the actual dispensing inventory through a pharmacy. The focused guide to metronidazole extended release 750mg provides a narrower look at that issue and should not be read as a universal substitution recommendation.
No public NDC query by itself establishes a manufacturer’s comparative product quality, price competitiveness or delivery performance. Unsupported rankings would be speculation rather than information useful to a patient.
Instead, a pharmacist can confirm an approved formulation and inspect the actual dispensed manufacturer’s label when the prescriber has specified a product or excipient restriction.
Suppose an oral metronidazole bottle shows a labeler unfamiliar to the patient. Record the full NDC, 250 mg or 500 mg strength, oral-tablet dosage form and package identity. Look up the precise NDC in DailyMed and read whether the label is marked repackaged or lists a source NDC. The archived Cambridge Therapeutics tablet record is a good illustration of why labeler and actual manufacturer cannot simply be treated as synonyms.
Then compare the reported approval application with FDA records, review therapeutic equivalence where applicable, and ask the dispensing pharmacist whether the proposed product matches the prescription. If a changed manufacturer is relevant to an excipient allergy, flag the issue for pharmacy review. A different labeler or imprint, by itself, proves neither inferior quality nor a safety problem.
Ask who labeled the product, whether the proposed formulation is FDA-approved, which application and TE code apply, and whether the supplied package matches the prescription.
If the exact company, dosage form or product cannot be verified, ask for a documented clarification instead of guessing based on a logo, online supplier list or a claim that all metronidazole products are identical.
An oral 500 mg refill may have a different company name or NDC from the previous supply. Rather than infer a change in approval status, the patient can ask the pharmacist to read back the dosage form, exact strength and listed application. A DailyMed listing may disclose a source NDC when the supplier repackages an approved product; this is an administrative relationship, not a new therapeutic class.
For a practical regulatory check, compare FDA approval and equivalence for the exact oral tablet application, then verify the dispensed tablet by its imprint, label and directions. Do not extrapolate equivalence from the metronidazole ingredient alone to oral suspension, 375 mg capsules or another route. A pharmacy can clarify the product; a website cannot certify its current supply.
A company may be listed on metronidazole 0.75% vaginal gel while another is listed on 0.75% skin gel. Both use metronidazole, but their labeled routes, package components and indications differ.
A useful index therefore groups the names under separate dosage-form and route headings before listing the labeler or application. Mixing those entries into one alphabetized manufacturer ranking would create false equivalence for pharmacy customers. A related route- or product-specific discussion appears at metronidazole vaginal gel 0.75%; consult it for details, not an unauthorized substitute.
A DailyMed SPL may include establishments, repackagers and distributor information, but the precise role needs to be read rather than inferred. Country information for one listed facility does not prove that every package bearing the brand was made there.
Marketing dates in a listing are also not retail-stock feeds. A pharmacist can verify what physical item is being dispensed; a public manufacturer guide should not invent national inventory, current supplier relationships or a best-quality league table. A related route- or product-specific discussion appears at metronidazole gel 0.75% topical; consult it for details, not an unauthorized substitute.
For a manufacturer-related pharmacy inquiry, the most useful details are the prescribed drug, oral or nonoral route, strength, dosage form, manufacturer restriction if any, and any particular ingredient sensitivity. A pharmacist can distinguish a permissible same-product generic dispense from a proposal that would change route, strength or vehicle. When the question involves a different active ingredient or treatment course, the prescriber must decide whether the alternative is clinically appropriate.
Do not pick a manufacturer solely because a search result shows an NDC or a familiar national brand. FDA approval, listing and warehouse distribution are separate issues. The final dispensing label identifies the product actually supplied; it should be checked against the prescription and not against an illustrative historical NDC in this guide.
When evaluating metronidazole generic manufacturers, ask the pharmacist to match the prescription to the FDA-labeled dosage form, active ingredient, full strength and package. For oral medicine, the release mechanism may matter; for vaginal or skin products, administration route and device matter. If a store search omits these details, request the complete product identity before making a payment decision.
For metronidazole generic manufacturers, legitimate U.S. dispensing requires an appropriate prescription. A licensed online pharmacy should have verifiable credentials and a pharmacist to answer questions. Never use an undisclosed overseas seller or a no-prescription offer as proof of equivalent medicine. Lists and application records do not establish current inventory, distribution or delivery time.
Comparing two metronidazole manufacturer or labeler listings makes financial sense only after the pharmacy confirms that the offered items meet the same prescription requirements. Price can depend on the package size, dispensing pharmacy, plan rules and exact approved product. A lower-cost topical gel listing is not an alternative to an oral tablet prescription merely because it shares the active ingredient.
If a product is unavailable, ask the pharmacist whether an appropriately approved and legally substitutable product can be supplied. A formulation or therapeutic change requires the prescribing clinician as appropriate. For how to verify supply without implying that an FDA NDC equals stock, consult metronidazole availability. Avoid unsupported quality rankings, factory-origin guesses and current manufacturer inventory claims.
Not necessarily. It identifies a listing and labeler; manufacturing relationships may be different.
No. FDA explicitly states that NDC assignment does not prove approval.
Yes. Labelers may be manufacturers, repackagers, relabelers or private-label entities.
Use the FDA Orange Book and related application and therapeutic-equivalence records.
No. DailyMed contains labeling information and cannot confirm pharmacy inventory.
No. They have different routes and product labels.
No. Historical listing and market-status data must be interpreted separately from inventory.
No. A code change alone is not evidence of inferior quality.
No reliable FDA ranking of retail metronidazole manufacturers should be inferred from listings.
Ask for the exact approved drug, route, strength, labeler, reference product and permitted substitution status.